H.C. Wainwright Thinks Alliqua’s Stock is Going to Recover

By Austin Angelo

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Alliqua (NASDAQ: ALQA) today. The company’s shares opened today at $0.61, close to its 52-week low of $0.58.

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -21.6% and a 23.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Spectrum Pharmaceuticals, and IntelGenx Technologies.

Alliqua has an analyst consensus of Moderate Buy.

The company has a one year high of $3.06 and a one year low of $0.58. Currently, Alliqua has an average volume of 71.19K.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Jeffrey Sklar, a Director at ALQA bought 1,500 shares for a total of $4,425.

Alliqua BioMedical, Inc. operates as a biomedical company, provides wound care solutions that will enable surgeons, clinicians, and wound care practitioners to address the entire spectrum of challenges presented by chronic and advanced wounds. The company was founded on October 27, 1997 and is headquartered in Yardley, PA.